Skip to main content

Market Overview

Deutsche Bank Remains Positive on Arrowhead Research Despite Weakness


In a report published Tuesday, Deutsche Bank analyst Alethia Young reiterated a Buy rating and $45.00 price target on Arrowhead Research (NASDAQ: ARWR).

In the report, Deutsche Bank noted, “There is weakness in overall biotech sentiment that has put pressure on ARWR shares. We remain positive on risk reward into their data in 3q. Arrowhead announced that they have started dosing in Hong Kong. Timelines remain on track for 3q14 top line data in their single dose study with HBV infected patients. Arrowhead remains the leader on timelines.

"We project arrowhead is about a year ahead since they completed their healthy study in late 2013. We think the ISIS announcement provides corroborating evidence that antisense/ RNA interference is a reasonable way to target HBV (in particular surface antigen). We see this as an attractive program for ISIS. We think the HBV market is large enough to have many developers in the space. Dosing frequency, efficacy, and tolerability will be important factors in determining long-term profile.”

Arrowhead Research Corp. closed on Monday at $17.37.

Latest Ratings for ARWR

Feb 2021B. Riley FBRMaintainsBuy
Feb 2021Piper SandlerMaintainsOverweight
Feb 2021HC Wainwright & Co.MaintainsBuy

View More Analyst Ratings for ARWR
View the Latest Analyst Ratings


Related Articles (ARWR)

View Comments and Join the Discussion!

Posted-In: Alethia Young Deutsche BankAnalyst Color Reiteration Analyst Ratings

Latest Ratings

GIKColliers SecuritiesInitiates Coverage On14.0
SANWLake StreetInitiates Coverage On6.0
LILAMorgan StanleyDowngrades15.0
BEJP MorganUpgrades36.0
NEXACredit SuisseUpgrades11.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at